Introduction
============

Hemophagocytic lymphohistiocytosis (HLH) is a severe life-threatening disorder, characterized by hyperactivation of macrophages due to uncontrolled hypersecretion of inflammatory cytokines. Patients with HLH have a wide clinical spectrum but typically present with high fever, splenomegaly, cytopenias, coagulation abnormalities, and tissue evidence of hemophagocytosis.[@b1-cmar-11-997],[@b2-cmar-11-997] HLH can be classified into two distinct forms: familial hemophagocytic lymphohistiocytosis (primary HLH) and secondary hemophagocytic lymphohistiocytosis (secondary HLH).[@b3-cmar-11-997],[@b4-cmar-11-997] Secondary HLH is associated with various conditions including infections, connective tissue diseases, and hematological malignancies, mainly non-Hodgkin's lymphoma (NHL).[@b5-cmar-11-997],[@b6-cmar-11-997] Large studies have suggested that natural killer (NK)/T-cell lymphoma is the predominant trigger of lymphoma-associated hemophagocytic syndrome (LAHS) in Asia.[@b7-cmar-11-997],[@b8-cmar-11-997] NK/T-cell lymphoma includes two subtypes: upper aerodigestive tract NK/T-cell lymphoma (UNKTL) and extra-upper aerodigestive tract NK/T-cell lymphoma (EUNKTL).[@b9-cmar-11-997] Briefly, UNKTL comprised all lymphomas confined to nasal cavity, nasopharynx, and the upper aerodigestive tract, whereas EUNKTL included lymphomas occurring at all other sites. Due to the rarity and heterogeneity of HLH, there have been few investigations with large sample size of NK/T-cell LAHS. In this retrospective study, we analyzed the clinical records of 28 patients with extranodal NK/T-cell lymphoma-associated HLH, in an attempt to have better understanding of the clinical characteristics and prognostic factors of the disease.

Patients and methods
====================

A total of 28 patients who were diagnosed as extranodal NK/T-cell lymphoma-associated HLH and treated in Shanghai Cancer Center, China from January 2006 to July 2017, were included in this retrospective study. This study was approved by the Institutional Review Board of the Fudan University Shanghai Cancer Center. All patients signed separate informed consent forms for reviewing their medical records and research. All pathological results were reviewed by experienced pathologists in pathology department of Shanghai Cancer Center. All patients were pathologically confirmed of NK/T-cell lymphoma through biopsy samples according to the criteria of the WHO.[@b10-cmar-11-997] HLH was diagnosed according to the criteria proposed by the Histiocyte Society in 2004.[@b2-cmar-11-997] In the absence of a known gene mutation, a diagnosis of HLH can be made with at least five of the following eight criteria: fever, splenomegaly, cytopenias in two or more cell lines, hypertriglyceridemia and/or hypofibrinogenemia, hemophagocytosis, low or absent activity in NK cells, ferritin concentration \>500 µg/L, or soluble CD25 concentration \>2,400 U/mL. The demographic details and clinical and laboratory features of the patients are summarized in [Table 1](#t1-cmar-11-997){ref-type="table"}. For each patient, the following data before or at the time of HLH diagnosis were collected: patient demographics, UNKTL or EUNKTL, Ann Arbor stage, NK/T-cell lymphoma prognostic index (NKPI) score,[@b11-cmar-11-997] Eastern Cooperative Oncology Group (ECOG) performance score, fever, bone marrow involvement, laboratory tests, type of treatment, and survival status.

Statistical analyses
--------------------

All analyses were performed using PASW statistics 18 (SPSS Inc., Chicago, IL, USA). Overall survival (OS) was measured from the date of diagnosis to the date of death owing to any cause or the date of last follow-up. Patients who died within 2 weeks after diagnosis of NK/T-cell LAHS were defined as short survival group, and those who survived \>2 months were defined as long survival group. Chi-squared test was used to compare the clinical and laboratory data for shorter survival group and longer survival group. For survival analyses, Kaplan--Meier survival curves were constructed, and differences were tested by the log-rank test. All *P*-values were two-sided, and the results were considered significant if *P*\<0.05.

Results
=======

Patient characteristics
-----------------------

All 28 cases were from hospitalized patients, of whom 18 (64.3%) were men and 10 (35.7%) were women. The median age was 42 years (range 19--74 years) at the time of HLH diagnosis. According to Ann Arbor staging criteria, 19 (67.9%) patients were at stage I/II, and 9 (32.1%) were at stage III/IV. NKPI score (including the presence of B symptoms, stage III or IV, elevated lactic dehydrogenase \[LDH\] level, and lymph node involvement) was available for all patients, and accordingly, 18 patients had NKPI score of 0 or 1 and 10 patients had NKPI score of ≥2. Twelve patients (42.9%) were diagnosed as EUNKTL. Ten patients (35.7%) had skin involvement. Symptoms of NK/T-cell LAHS in our study were non-specific including, most commonly, fever (96.4%) and splenomegaly (81.5%). Most patients were EBER positive (93.8%). Concerning the laboratory findings, the most common were hyperferritinemia (91.7%), grade III/ IV thrombocytopenia (64.3%), hypertriglyceridemia (48%), severe anemia (46.4%), hypofibrinogenemia (45%), and grade III/IV neutropenia (32.1%). Thrombocytopenia and neutropenia were assessed according to CTCAE version 4.0, and grade III/IV thrombocytopenia represented platelet count of \<50\*10E9/L. Grade III/IV neutropenia represented neutrophilic granulocyte count of \<1\*10E9/L. Basic characteristics of the patients concerning the clinical and laboratory parameters are recorded ([Table 1](#t1-cmar-11-997){ref-type="table"}).

Treatment and response
----------------------

After the diagnosis of extranodal NK/T-cell lymphoma, 16 patients received DICE (ifosfamide, etoposide, cisplatine, and dexamethasone) regimen with or without involved-field radiotherapy as first-line chemotherapy. Six patients received asparaginase-based chemotherapy regimen, and the other patients received CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) regimen. The complete response rate was achieved in 14 (50%) patients. Six (21.4%) patients achieved partial response giving an objective response rate of 71.4% according to the response assessment criteria proposed by Cheson et al.[@b12-cmar-11-997] Thirteen patients with refractory or relapsing disease were treated with asparaginase-based regimen as salvage therapy achieved an ORR of 28.6%. The median time from diagnosis of NK/T-cell lymphoma to the onset of HLH was 9 months (1--228 months). After the onset of HLH, patients were treated with chemotherapy following the HLH-2004 guideline proposed by the Histiocyte Society. The remission rate of the treatment was 23.8% (5/21), and statistically significant difference was found between clinical response to treatment and patients' OS (*P*=0.00021). One patient in our study received allo-allogeneic hematopoietic stem cell transplant after treatment of HLH and was still alive at the time of last follow-up. The interval between the diagnosis of NK/T-cell LAHS and death/last contact was between 4 and 701 days with the median interval of 15 days ([Figure 1](#f1-cmar-11-997){ref-type="fig"}).

Comparison of patients' characteristics between the longer survival group and the shorter survival group
--------------------------------------------------------------------------------------------------------

In our study, we divided patients into two groups: patients died within 2 weeks after diagnosis of NK/T-cell LAHS were defined as short survival group (n=13), and those who survived \>2 months after diagnosis of NK/T-cell LAHS were defined as long survival group (n=6). We noticed that splenomegaly was detected more in short survival group, and the difference is of statistically significance (*P*\<0.001). We also found that hypofibrinogenemia and LDH \>1,000 U/L at diagnosis of HLH were also statistically significant different (*P*=0.026, *P*=0.007) between the two groups. Other factors such as gender, age at diagnosis of HLH, ECOG, stage, EBV-encoded RNA (EBER) status, anemia, and thrombocytopenia were not statistically different between two groups ([Table 2](#t2-cmar-11-997){ref-type="table"}).

The impact of patients' clinical and laboratory parameters on OS
----------------------------------------------------------------

Kaplan--Meier analysis indicated that patients with higher LDH at diagnosis of HLH had a lower OS compared to those with lower levels of LDH (*P*=0.002, [Figure 2A](#f2-cmar-11-997){ref-type="fig"}). An association was found between hypofibrinogenemia and a worse OS (*P*=0.003; [Figure 2B](#f2-cmar-11-997){ref-type="fig"}). Presence of splenomegaly was also correlated with a poor OS (*P*=0.003; [Figure 2C](#f2-cmar-11-997){ref-type="fig"}).

Discussion
==========

The onset of HLH during or after the treatment of NK/T-cell lymphoma is a rare, but often catastrophic event. In most cases even intensive therapeutic measures cannot prevent the lethal outcome.[@b13-cmar-11-997] Therefore, it would be highly valuable to rapidly identify clinical and/or laboratory risk factors of the disease. Here, in this retrospective study, we concentrated on the clinical and laboratory features, and prognostic factors of NK/T-cell lymphoma patients diagnosed with HLH.

The mortality rate within 1 month after diagnosis of NHL-related HLH was reported as high as 20%.[@b14-cmar-11-997] NK/T-cell lymphoma had a worse prognosis than B-cell lymphoma, with 5-year survival rate of \<15%.[@b15-cmar-11-997] In our study, mortality rate was 96.4% with only one patient survived, and the median survival was 15 days, which underscores the rapid progression and poor prognosis of the disease.

To clarify the increased risk for NK/T-cell lymphoma-associated HLH, we compared the patients' characteristics in our cohort with some previous studies.[@b9-cmar-11-997],[@b11-cmar-11-997] [Table 3](#t3-cmar-11-997){ref-type="table"} indicates that increased risk for HLH was associated with higher ECOG scores (ECOG 2--3; *P*\<0.001, *P*\<0.001), primary site of involvement (EUNKTL; *P*\<0.001, *P*=0.006), and cutaneous involvement (*P*\<0.001). Previous studies have reported that splenomegaly and elevated LDH levels affect patient prognosis.[@b16-cmar-11-997],[@b17-cmar-11-997] Besides, in our study, we also found that hypofibrinogenemia was an adverse prognostic factor of HLH.

Treatment for NK/T-cell LAHS remains a challenge. In our study, we mainly carried out treatment according to HLH-04 guidelines. We found there was statistically significant difference between treatment response and patients' OS (*P*=0.00021), which was consistent with other previous reports.[@b5-cmar-11-997],[@b18-cmar-11-997] Previous reports also recommended that those who respond well with NK/T-cell LAHS initial induction therapy should be actively engaged in HSCT.[@b19-cmar-11-997],[@b20-cmar-11-997] However, even with the currently recommended therapy, HLH is frequently a fatal condition with a high rate of mortality. Also some investigators suggested doctors should simultaneously consider controlling high inflammatory cytokine storm and treating NK--T-cell lymphoma.[@b21-cmar-11-997] Further clinical trials should be carried out to explore better therapeutic procedures, especially for those who do not respond to first line treatment regimens.

There are some limitations of our study. First, because of the long period of study, the number of copies of EBV-DNA was not routinely detected; the association between the levels of EBV-DNA and patients' OS were not analyzed. Second, we only enrolled and analyzed hospitalized patients, the number of cases in this study was relatively small, and only one patient received HSCT.

Conclusion
==========

In summary, NK/T-cell LAHS is highly lethal and with extremely poor prognosis. Our data indicated that the levels of LDH, fibrinogen, and presence of splenomegaly were prognostic factors of the disease. Higher ECOG scores, EUNKTL, and cutaneous involvement were risk factors of NK/T-cell LAHS. Additional independent, prospective clinical trials will be needed to explore optimal treatment.
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![Survival of NK/T-cell LAHS patients\
**Note:** The overall survival of NK/T LAHS patients.\
**Abbreviations:** NK, natural killer; LAHS, lymphoma-associated hemophagocytic syndrome.](cmar-11-997Fig1){#f1-cmar-11-997}

![Correlations between levels of LDH, fibrinogen, and presence of splenomegaly and patient OS.\
**Note:** Kaplan--Meier analysis illustrating the association between levels of LDH (**A**), fibrinogen (**B**), presence of splenomegaly (**C**), and OS in NK/T-cell LAHS (meanings of blue and green lines are indicated in each panel).\
**Abbreviations:** LAHS, lymphoma-associated hemophagocytic syndrome; LDH, lactic dehydrogenase; NK, natural killer; OS, overall survival.](cmar-11-997Fig2){#f2-cmar-11-997}

###### 

Baseline characteristics of 28 patients with NK/T-cell LAHS

  Characteristics                  No. of patients   \%
  -------------------------------- ----------------- ------
  Gender                                             
   Male                            18                64.3
   Female                          10                35.7
  Age at diagnosis (years)                           
   \>60                            3                 10.7
   ≤60                             25                89.3
  ECOG                                               
   0--1                            13                46.4
   2--3                            15                53.6
  Ann Arbor stage                                    
   I + II                          19                67.9
   III + IV                        9                 32.1
  Bone marrow involvement (n=13)                     
   Yes                             3                 23.1
   No                              10                76.9
  LDH level before HLH (n=22)                        
   Normal                          13                59.1
   Elevated                        9                 40.9
  Subtypes                                           
   UNKTL                           16                57.1
   EUNKTL                          12                42.9
  EBER positive (n=16)                               
   Yes                             15                93.8
   No                              1                 6.2
  Cutaneous involvement                              
   Yes                             10                35.7
   No                              18                64.3
  NKPI                                               
   0--1                            18                64.3
   ≥2                              10                35.7
  Neutropenia                                        
   I/II                            8                 28.6
   III/IV                          9                 32.1
  No                               11                39.3
  Anemia                                             
   I/II                            15                53.6
   III/IV                          13                46.4
  Fever                                              
   Yes                             27                96.4
   No                              1                 3.6
  Splenomegaly (n=27)                                
   Yes                             22                81.5
   No                              5                 18.5
  Ferritin (ng/mL) (n=12)                            
   ≥500                            11                91.7
   \<500                           1                 8.3
  Fibrinogen (g/L) (n=20)                            
   ≤1                              9                 45
   \>1                             11                55
  Triglycerides (mmol/L) (n=25)                      
   ≥3.0                            12                48
   \<3.0                           13                52
  Thrombocytopenia                                   
   I/II                            10                35.7
   III/IV                          18                64.3
  LDH at HLH (U/L) (n=27)                            
   \>1,000                         11                40.7
   ≤1,000                          16                59.3

**Abbreviations:** EBER, EBV-encoded RNA; ECOG, Eastern Cooperative Oncology Group; EUNKTL, extra-upper aerodigestive tract NK/T-cell lymphoma; HLH, hemophagocytic lymphohistiocytosis; LDH, lactic dehydrogenase; NK, natural killer; NKPI, NK/T-cell lymphoma prognostic index; UNKTL, upper aerodigestive tract NK/T-cell lymphoma.

###### 

Characteristics of patients with NK/T LAHS between longer survival group and shorter survival group

  Characteristics          Shorter group   Longer group   *P*-value
  ------------------------ --------------- -------------- -----------
  Gender                                                  
   Male                    8               4              0.829
   Female                  5               2              
  Age at diagnosis                                        
   Mean ± SD               41.42±14.34     39.29±3.63     0.876
  Age at HLH                                              
   Mean ± SD               42.37±13.82     41.82±5.08     0.876
  ECOG                                                    
   0--1                    5               4              0.252
   2--3                    8               2              
  Ann Arbor stage                                         
   I + II                  10              4              0.637
   III + IV                3               2              
  LDH level before HLH                                    
   Normal                  6               3              1
   Elevated                4               2              
  Subtypes                                                
   UNKTL                   7               4              0.599
   EUNKTL                  6               2              
  EBER positive                                           
   Yes                     6               4              0.428
   No                      1               0              
  Cutaneous involvement                                   
   Yes                     6               3              0.876
   No                      7               3              
  Anemia                                                  
   I/II                    7               4              0.599
   III/IV                  6               2              
  Splenomegaly                                            
   Yes                     12              1              \<0.001
   No                      0               5              
  Ferritin (ng/mL)                                        
   ≥500                    1               4              0.121
   \<500                   1               0              
  Fibrinogen (g/L)                                        
   ≤1                      6               0              0.026
   \>1                     3               4              
  Triglycerides (mmol/L)                                  
   ≥3.0                    6               1              0.091
   \<3.0                   4               5              
  Thrombocytopenia                                        
   I/II                    4               3              0.419
   III/IV                  9               3              
  LDH at HLH (U/L)                                        
   \>1,000                 8               0              0.007
   ≤1,000                  4               6              

**Abbreviations:** EBER, EBV-encoded RNA; ECOG, Eastern Cooperative Oncology Group; EUNKTL, extra-upper aerodigestive tract NK/T-cell lymphoma; HLH, hemophagocytic lymphohistiocytosis; LDH, lactic dehydrogenase; NK, natural killer; NKPI, NK/T-cell lymphoma prognostic index; UNKTL, upper aerodigestive tract NK/T-cell lymphoma.

###### 

Comparison of patient characteristics in our study with two previous published studies

  Characteristics            Our study (FUSCC China)   Lee et al,[@b9-cmar-11-997] Korea   χ^2^     *P-*value   Kim et al,[@b11-cmar-11-997] Korea   χ^2^     *P-*value
  -------------------------- ------------------------- ----------------------------------- -------- ----------- ------------------------------------ -------- -----------
                                                                                                                                                              
  Gender                                                                                                                                                      
   Male                      18                        170                                 0.004    0.950       131                                  0.018    0.893
   Female                    10                        92                                                       77                                            
  Age at diagnosis (years)                                                                                                                                    
   \>60                      3                         55                                  1.670    0.196       141                                  33.796   \<0.001
   ≤60                       25                        207                                                      67                                            
  ECOG                                                                                                                                                        
   0--1                      13                        228                                 29.688   \<0.001     187                                  36.082   \<0.001
   2--3                      15                        34                                                       21                                            
  Ann Arbor stage                                                                                                                                             
   I + II                    19                        200                                 0.984    0.321       145                                  0.040    0.841
   III + IV                  9                         62                                                       63                                            
  LDH before HLH                                                                                                                                              
   Normal                    13                        166                                 0.159    0.69        125                                  0.008    0.927
   Elevated                  9                         96                                                       83                                            
  Subtypes                                                                                                                                                    
   UNKTL                     16                        222                                 13.085   \<0.001     167                                  7.592    0.006
   EUNKTL                    12                        40                                                       41                                            
  NKPI                                                                                                                                                        
   0--1                      18                        128                                 0.35     0.554       110                                  1.292    0.25
   ≥2                        10                        91                                                       98                                            
  Cutaneous involvement                                                                                                                                       
   Yes                       10                        7                                   50.049   \<0.001     NA                                            
   No                        18                        255                                                      NA                                            

**Abbreviations:** ECOG, Eastern Cooperative Oncology Group; EUNKTL, extra-upper aerodigestive tract NK/T-cell lymphoma; FUSCC, Fudan University Shanghai Cancer Center; HLH, hemophagocytic lymphohistiocytosis; LDH, lactic dehydrogenase; NKPI, NK/T-cell lymphoma prognostic index; UNKTL, upper aerodigestive tract NK/Tcell lymphoma.
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